<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sanofi Sa — News on 6ix</title>
<link>https://6ix.com/company/sanofi-sa</link>
<description>Latest news and press releases for Sanofi Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 05:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sanofi-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836194278dffbe2df13e4b7.webp</url>
<title>Sanofi Sa</title>
<link>https://6ix.com/company/sanofi-sa</link>
</image>
<item>
<title>Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofis-tzield-approved-in-the-us-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofis-tzield-approved-in-the-us-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children</guid>
<pubDate>Wed, 22 Apr 2026 05:05:00 GMT</pubDate>
<description>Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1D Paris, April 22, 2026. The US Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from e</description>
</item>
<item>
<title>Sanofi: Information concerning the total number of voting rights and shares - March 2026</title>
<link>https://6ix.com/company/sanofi-sa/news/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-march-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-march-2026</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial</description>
</item>
<item>
<title>Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofi-and-regenerons-dupixent-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofi-and-regenerons-dupixent-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU</description>
</item>
<item>
<title>Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians</title>
<link>https://6ix.com/company/sanofi-sa/news/sanofi-becomes-market-authorization-holder-for-nuvaxovidr-in-canada-expanding-covid-19-vaccine-choices-for-canadians</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/sanofi-becomes-market-authorization-holder-for-nuvaxovidr-in-canada-expanding-covid-19-vaccine-choices-for-canadians</guid>
<pubDate>Thu, 09 Apr 2026 14:00:00 GMT</pubDate>
<description>Sanofi today announces it has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi's commitment to building a diverse portfolio of best-in-class vaccines and addressing respiratory diseases for Canadians across their lifespan. Sanofi will make Nuvaxovid available in Canada for the fall 2026-2027 season.</description>
</item>
<item>
<title>Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents</title>
<link>https://6ix.com/company/sanofi-sa/news/sanofi-combined-general-meeting-of-april-29-2026-availability-of-preparatory-documents</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/sanofi-combined-general-meeting-of-april-29-2026-availability-of-preparatory-documents</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General</description>
</item>
<item>
<title>Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofis-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofis-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its</description>
</item>
<item>
<title>Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofis-rezurock-approved-in-the-eu-to-treat-chronic-graft-vs-host-disease</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofis-rezurock-approved-in-the-eu-to-treat-chronic-graft-vs-host-disease</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older</description>
</item>
<item>
<title>Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-aad-new-results-from-sanofis-amlitelimab-phase-3-studies-in-atopic-dermatitis-presented-in-late-breaking-research-session</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-aad-new-results-from-sanofis-amlitelimab-phase-3-studies-in-atopic-dermatitis-presented-in-late-breaking-research-session</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and</description>
</item>
<item>
<title>Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofis-sarclisa-subcutaneous-formulation-administered-via-on-body-injector-recommended-for-eu-approval-by-the-chmp-to-treat-multiple-myeloma</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofis-sarclisa-subcutaneous-formulation-administered-via-on-body-injector-recommended-for-eu-approval-by-the-chmp-to-treat-multiple-myeloma</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation</description>
</item>
<item>
<title>Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)</title>
<link>https://6ix.com/company/sanofi-sa/news/dupixentr-dupilumab-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-bp-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/dupixentr-dupilumab-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-bp-1</guid>
<pubDate>Tue, 24 Mar 2026 06:00:00 GMT</pubDate>
<description>Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,</description>
</item>
<item>
<title>Press release: Availability of the Q1 2026 aide-mémoire</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-availability-of-the-q1-2026-aide-memoire</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-availability-of-the-q1-2026-aide-memoire</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the</description>
</item>
<item>
<title>Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe</description>
</item>
<item>
<title>Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofis-venglustat-earns-breakthrough-therapy-designation-in-the-us-for-type-3-gaucher-disease</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofis-venglustat-earns-breakthrough-therapy-designation-in-the-us-for-type-3-gaucher-disease</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration</description>
</item>
<item>
<title>Sanofi: Information concerning the total number of voting rights and shares - February 2026</title>
<link>https://6ix.com/company/sanofi-sa/news/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-february-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-february-2026-1</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial</description>
</item>
<item>
<title>Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofis-board-of-directors-proposes-the-appointment-of-christel-heydemann-as-an-independent-director-8</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofis-board-of-directors-proposes-the-appointment-of-christel-heydemann-as-an-independent-director-8</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5, 2026. The Board of Directors of Sanofi</description>
</item>
<item>
<title>Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-filing-of-an-amendment-to-the-french-document-denregistrement-universel-containing-the-annual-financial-report</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-filing-of-an-amendment-to-the-french-document-denregistrement-universel-containing-the-annual-financial-report</guid>
<pubDate>Wed, 04 Mar 2026 17:30:00 GMT</pubDate>
<description>Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). This amendment notably includes additions to the report on corporate governance established in accordance with French law. This document is available on the c</description>
</item>
<item>
<title>Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofis-rilzabrutinib-earns-orphan-drug-designation-in-japan-for-igg4-related-disease</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofis-rilzabrutinib-earns-orphan-drug-designation-in-japan-for-igg4-related-disease</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of</description>
</item>
<item>
<title>Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-sanofi-and-regenerons-dupixent-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-in-young-children-with-ongoing-symptoms-despite-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-sanofi-and-regenerons-dupixent-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-in-young-children-with-ongoing-symptoms-despite-treatment</guid>
<pubDate>Fri, 27 Feb 2026 12:03:00 GMT</pubDate>
<description>Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children Paris and Tarryt</description>
</item>
<item>
<title>Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment</title>
<link>https://6ix.com/company/sanofi-sa/news/dupixentr-dupilumab-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-csu-in-young-children-with-ongoing-symptoms-despite-treatment-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/dupixentr-dupilumab-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-csu-in-young-children-with-ongoing-symptoms-despite-treatment-1</guid>
<pubDate>Fri, 27 Feb 2026 12:00:00 GMT</pubDate>
<description>If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Com</description>
</item>
<item>
<title>Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness</title>
<link>https://6ix.com/company/sanofi-sa/news/press-release-acoziborole-winthrop-developed-by-dndi-and-sanofi-receives-chmp-positive-opinion-as-three-tablet-single-dose-treatment-for-most-common-form-of-sleeping-sickness</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa/news/press-release-acoziborole-winthrop-developed-by-dndi-and-sanofi-receives-chmp-positive-opinion-as-three-tablet-single-dose-treatment-for-most-common-form-of-sleeping-sickness</guid>
<pubDate>Fri, 27 Feb 2026 10:55:00 GMT</pubDate>
<description>Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 study demonstrating up to 96 percent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sicknessThe therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens and help support th</description>
</item>
</channel>
</rss>